The US Food and Drug Administration (FDA) has issued the first guidance on the use of artificial intelligence (AI) for the development of drug and biological products. The draft guidance provides recommendations on the use of AI to support a regulatory decision about a drug or biological product’s safety, effectiveness or quality. Specifically, it provides […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!